• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

BRCA1/2 pathogenic variants are associated with an increased risk of male breast, pancreatic, and stomach cancer.

byKassandra McFarlaneandSze Wah Samuel Chan
January 31, 2022
in Chronic Disease, Genetics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Pathogenic variants of BRCA1 or BRCA2 are associated with an increased risk of pancreatic and stomach cancer in both sexes

2. Only BRCA2 carriers have an increased risk of prostate cancer

Evidence Rating Level: 2 (Good)

Study Rundown: Pathogenic variants (PVs) of BRCA1 and BRCA2 are known to be associated with an increased risk for female breast and ovarian cancer, however, their association with other cancers is unclear. This study aimed to determine age-specific risk estimates for cancers associated with BRCA1/2 PVs. BRCA1 PVs were found to be associated with male breast (relative risk (RR) = 4.30), pancreatic (RR = 2.36), and stomach cancer (RR = 2.17). BRCA2 PVs were associated with those same cancers (RR = 44.0, 3.34, and 3.69, respectively) as well as with prostate cancer (RR = 2.22). Age-specific absolute risks (AR) for cancer were 0.4% (BRCA1) and 3.8% (BRCA2) at 80 years old for male breast cancer; 2.3% and 3.0% pancreatic cancer risk for BRCA1 and BRCA2 carriers; stomach cancer AR was 1.6% for male and 0.7% for female BRCA1 carriers, while it was 3.5% for BRCA2 carriers overall. BRCA2 was associated with increased AR for prostate cancer at 26.9% by 80 years old, and 33.1% by 85 years. Limitations to this study include its retrospective and self-reported family cancer history, which may be inaccurate; results were presented without multiple testing adjustments; as well as missing data on environmental and other genetic factors. Overall, BRCA1/2 PVs are associated with increased risk of pancreatic, stomach, and male breast cancer; only BRCA2 is associated with heightened prostate cancer risk.

Click to read the study in The American Society of Clinical Oncology

Relevant Reading: Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

In-Depth [retrospective cohort]: This retrospective, family-based study included 3,184 BRCA1 and 2,157 BRCA2 families. BRCA1 PVs were found to be associated with the following cancers: male breast (RR = 4.30; 95% confidence interval (CI), 1.09 to 16.96), pancreatic (RR = 2.36; 95% CI, 1.51 to 3.68), and stomach cancer (RR = 2.17; 95% CI, 1.25 to 3.77). BRCA2 PVs were also associated: male breast (RR = 44.0; 95% CI, 21.3 to 90.9), pancreatic (RR = 3.34; 95% CI, 2.21 to 5.06), and stomach (RR = 3.69; 95% CI, 2.40 to 5.67) in addition to prostate cancer (RR = 2.22; 95% CI, 1.63 to 3.03). Age-specific AR for male breast cancer was 0.4% (95% CI, 0.1% to 1.5%) for BRCA1 and 3.8% (95% CI, 1.9% to 7.7%) for BRCA2 at 80 years old. Pancreatic cancer risk was 2.3% and 3.0% for BRCA1 and BRCA2 carriers. The AR for stomach cancer was 1.6% (95% CI, 0.7% to 4.0%) for male and 0.7% (95% CI, 0.3% to 1.7%) for female BRCA1 carriers, while it was ~3.5% for BRCA2 carriers overall. BRCA2 was associated with increased AR for prostate cancer at 26.9% (95% CI, 20.5% to 34.7%) by 80 years old, and 33.1% (95% CI, 25.5% to 42.2%) by 85 years. Notably, this study did not show any other clear associations with other primary cancers which helps refine cancer risk estimates for patients with these PVs.

RELATED REPORTS

Breast MRI most sensitive screening modality in high-risk patients [Classics Series]

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

Variants in the SPTLC1 gene associated with juvenile amyotrophic lateral sclerosis

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BRCA mutationcancer geneticsgenetic screening
Previous Post

Hybrid closed-loop therapy improves glycemic control for children with Type 1 Diabetes

Next Post

Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Breast MRI most sensitive screening modality in high-risk patients [Classics Series]

August 9, 2022
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

March 21, 2022
Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography
Chronic Disease

Variants in the SPTLC1 gene associated with juvenile amyotrophic lateral sclerosis

September 3, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Carriers of genetic variants of inherited cardiomyopathies and arrhythmias associated with unexplained sudden cardiac death

June 7, 2021
Next Post
Recurrence of endometrial hyperplasia following medical therapy is common

Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy

Quick Take: Left ventricular mechanical dispersion predicts arrhythmic risk in mitral valve prolapse

Tricuspid repair in patients with mitral regurgitation offers clinical benefits

Parents with poor sleep quality report sleep problems in kids

Australian RSV epidemic seasonality – but not severity – altered by COVID-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options